The SGLT2 inhibitor dapagliflozin has been shown to decrease AF incidence in a sub-analysis of the DECLARE-TIMI 58 trial [6] and in a meta-analysis [7]. The gene discussed is SLC5A2; the disease is atrial fibrillation.